

PHẦN THỨ BA  
TÀI LIỆU NGHIÊN CỨU

CHƯƠNG THỨ NHẤT  
TÀI LIỆU TÂY PHƯƠNG

# TÀI LIỆU TÂY PHƯƠNG

## 1. Tài liệu tổng quát

### 1.1. Impotence,

*Diagnosis and management of erectile dysfunction*, Bennett AH ed., WB Saunders company, 1994.

### 1.2. Impotence,

*Urologic Clinics of America*, 1995; 22: 699-886.

## 2. Trên các tạp chí

### 2.1. Abram HS, Hester LR, Sheridan WF, Epstein GM.

*Sexual functioning in patients with chronic renal failure*. *J Nerv Ment Dis* 1975; 160: 220-226.

### 2.2. Abramov LA.

*Sexual life and Frigidity among women developing acute myocardial infarction*. *Psychosom Med* 1976; 38: 418-425.

### 2.3. Althof SE, Turner LA, Levine SB, Risen C, Kursh ED, Bodner D, Resnik M.

*Intracavernosal injection in the treatment of impotence: a prospective study of sexual, psychological, and marital functioning*. *J Sex Marital Ther* 1987; 13: 155-167.

### 2.4. Amarenco G, Kedraon J.

*Rapport des investigations électrophysiologiques périnéales dans les dysfontions érectiles*, *Ann Med Intern* 1993; 144(6); 383-388.

### 2.5. American Urological Association.

*Special issue: impotence/infertility*. *J Urol* 1993; 149 (5).

### 2.6. Andersson KE, Wagner G.

*Physiology of penile erection*. *Physiol Rev* 1995; 75: 191-236.

### 2.7. Benet AE, Melman A.

*The epidemiology of erectile dysfunction*. *Urol Clin North Am* 1995; 22: 699-709.

### 2.8. Benet AE, Sharaby JS, Melman A.

*Male erectile dysfunction assessment and treatment options*. *Compr Ther* 1994; 20: 669-673.

2.9. Bondil P, Blachère P.

*Le traitement de l'insuffisance érectile: quels sont les objectifs et les méthodes?* Prog Urol 1998; 8: 17-31.

2.10. Bondil P, Wespes E.

*Anatomie et physiologie de l'érection, rapport du 86è Congrès de l'AFU.* Orog Urol 1992; 2: 726-857.

2.11. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ.

*Sildenafil, a novel effective oral therapy for male erectile dysfunction.* Br J Urol. 1996; 78: 257-261.

2.12. Brock GB, Lue TF.

*Drug-induced male sexual dysfunction: an update.* Drug Safety 1993, 8: 417.

2.13. Bors E, Comarr AE.

*Neurological disturbances of sexual function with special reference to 529 patients with spinal cord injury.* Urol Surv 1960; 10: 191-222.

2.14. Bunett AL.

*Nitric oxide in the penis: physiology and pathology.* J Urol 1997; 157: 320-324.

2.15. Buvat J.

*La première consultation de l'impuissant.* J Urologie 1991; 97: 23-27.

2.16. Buvat J.

*Modèle physiopathologique des dysfonctions sexuelles à l'usage des somaticiens.* Acta Urol Belg 1989; 57: 155-162.

2.17. Buvat J.

*Vécu du diabète insulino-dépendant: un facteur de risque pour la sexualité.* In: *Fonction sexuelle et reproductrice du diabétique.* Progrès en Andrologie 2. Buvat J, Drodowsky M eds, Doin, Paris, 1989: 19-28.

2.18. Buvat J, Hermabessiere J.

*Perturbations iatrogènes de la sexualité.* Progrès en Andrologie 1. Doin, Paris; 1987: 124p.

2.19. Buvat J, Buvat-Herbaut M, Lemaire A, Marcolin G, Quittelier E.

*Recent developments in the clinical assessment and diagnosis of érectile dysfunction.* In: *Annual Review of Sex Research*, Bancroft J, Davis C, Weinstein D eds. Soc Sci Study Sex, 1990; Vol 1: 265-308.

2.20. Buvat J, Lemaire A.

*Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost effective strategy.* J Urol 1997; 158: 1764-1767.

2.21. Buvat J, Lemaire A, Ratajczyk J.

*Rôle des hormones dans les dysfonctions sexuelles, l'homosexualité, le transsexualisme et les comportements sexuels déviants. Conséquences diagnostiques et thérapeutiques.* Contracept Fertil Sex 1996; 24: 834-846.

2.22. Buvat J.

*Hormones et comportement sexuel de l'homme: données physiologiques et physiopathologiques.* Contr Fertil Sex 1996, 24: 767-778.

2.23. Cogen R, Steinman W .

*Sexual function praticien elderly men of lower socio-economic status.* J Fam Pract 1990; 31: 162-166.

2.24. Cornely CM, Schade RR, Van Thiel DH, Gavalier JS.

*Chronic advanced liver diseases and impotence: cause and effect.* Hepatology 1984; 4: 1227-1230.

2.25. Cornud F, Amar T, Hamida K, Casanova JM, Aynand O, Moresu SF.

*Echo-doppler avec imagerie couleur des artères caverneuses.* Andrologie 1996; 6 (4): 387-394.

2.26. Davey Smith G, Frankel S, Yarmell J.

*Sex and death : are they related? Findings from the Caerphilly cohort study.* Br Med J 1997; 315: 1641-1644.

2.27. Delavierre D, Peneau M, Ibrahim H.

*Injections intra-caverneuses.* Encycl Med Chir (Elsevier. Paris) Néphrologie-Urologie, Fa 19-395-A-10, 1996; 3p.

2.28. De Palma RG.

*Vascular Surgery for impotence : a review.* Int J Impot Res 1997; 9: 61-67.

2.29. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB .

*Impotence and its medical and psychological correlates, results of the Massachusetts Male Aging Study.* J Urol 1994; 151: 54-58.

2.30. Fletcher EC, Martin RJ.

*Sexual dysfunction and erectile impotence chronic obstructive pulmonary disease.* Chest 1982; 81: 413-421.

2.31. Goldstein I, Siroky MB, Sax DS, Krane RJ.

*Neurourologic abnormalities in multiple sclerosis.* J Urol 1982; 28: 541-545.

2.32. Hatzichristou GF.

*Current treatment and future perspectives for erectile dysfunction.* Int J Impot Res 1998; 10 (suppl. 1): 3-13.

2.33. Ignarro LJ, Lippton H, Edward JC et al.

*Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.* J Pharmacol Exp Ther 1981; 218: 739-749.

2.34. Jensen SB.

*Emotional aspects in a chronic disease: a study of 101 insulin treated diabetics.* Int J Rehabil Res 1989; 9: 13-20.

2.35. Jonler M, Moon T, Brannan W, Stone NN, Heisey D, Bruskevitz RC.

*The effect of age, ethnicity and geographical location on impotence and quality of life.* Br J Urol 1995; 75: 651-655.

2.36. Juliano F, Knellesen S, Dreyfus JP, Pasturaud JP, Jardin A.

*Troubles de l'erection en France: Données épidémiologiques.* Progr Urol 1995; 5 (suppl. 1): 52 A.

2.37. Juliano F, Knellesen S, Paturaud JP, Jardin A.

*Epidemiologic study of erectile dysfunction in France.* 12<sup>e</sup> Congrès de l'European Association of Urology, Paris, Septembre 1996; abstract 934.

2.38. Juliano F, Rampin O, Benoit G, Jardin A.

*Pharmacologie périphérique de l'erection.* Prog Urol 1997; 7: 24-33.

2.39. Juliano F, Rampin O, Benoit G, Jardin A.

*Pharmacologie périphérique de l'erection.* Prog Urol 1997; 7: 24-33.

2.40. Kim N, Azadzo KM, Goldstein I, Saenz de Tejada I.

*A nitric oxide-like factor mediates nonadrenergi-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle.* J Clin Invest 1991; 88: 112-118.

2.41. Lerner SE, Melman A, Christ GJ.

*A review of erectile dysfunction: new insights and more questions.* J Urol 1993; 149: 1246-1255.

2.42. Lewis RW, Witherington R.

*External vacuum therapy for erectile dysfunction: use and results.* World J Urol 1997; 15: 78-82.

2.43. Lue TF.

*Impotence: a patient's goal-directed approach to treatment.* World J Urol 1990; 8: 67-74.

2.44. Lugnier C, Komasa N.

*Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role of vasodilatation?* Eur Heart J 1993; 14 (suppl, 1) : 141-148.

2.45. Mac Culloch DK, Young RJ, Prescott RJ.

*The natural history of impotence in diabetic men.* Diabetologia 1984; 26: 437-440.

2.46. Meinhardt W, Kropman RF, Vermeij P, Lycklama A, Nijeholt AAB, Zwartendijk J.

*The influence of medication on erectile function.* Int J Impot Res 1997; 9: 17-26.

2.47. Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH.

*Clinical guidelines panel on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction.* J Urol 1996; 156: 2007-2011.

2.48. Morale A, Heaton JPW, Condra M.

*The pharmacology of impotence. In: Impotence, diagnosis and management of erectile dysfunction.* Bennet AH Ed, WD Saunders. Philadelphia 1989: 145-155.

2.49. NIH Consensus Development Panel on impotence. JAMA 1993; 270 (1): 83-90.

2.50. Palmore EB.

*Predictors of the longevity difference: a 25-year follow-up.* Gerontologist 1982; 6: 513-518.

2.51. Person G.

*Five-year mortality in a 70-year older urban population in relation to psychiatric diagnosis, personality, sexuality and early parental death.* Acta Psychiatr Scand 1981; 64: 244-253.

2.52. Rampin O, Giuliano F, Benoit G, Jardin A.

*Commande nerveuse centrale de l'érection.* Prog Urol 1997; 7: 17-23.

- 2.53. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ.  
*Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission.* N Engl J Med 1992; 326: 90-94.
- 2.54. Riley AJ, Athanasiadis L.  
*Impotence and its non-surgical management.* Br J Clin Pract 1997; 51: 99-105.
- 2.55. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A.  
*The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction.* Urology 1997; 49: 822-830.
- 2.56. Rossi D, Ayuso D, Rattier C, Bladou F, Hermanowicz M, Serment G.  
*Clinical experience with 80 inflatable penile prostheses.* Eur Urol 1997; 31: 335-338.
- 2.57. Sarrmon JP, Bertrand N, Malavaud B, Rischann P.  
*Microvascularisation of the penis in vascular impotence.* Int J Impot Res 1997; 9: 127-133.
- 2.58. Sharlip I.  
*Does natural erectile function improve following intra-cavernous injections of vasoactive drugs?* Int J Impot Res 1997; 9: 193-196.
- 2.59. Sharlip I.  
*The incredible results of penile vascular surgery.* Int J Impot Res 1990; 3: 1-6
- 2.60. SOFRES.  
*Etudes SOFRES sur l'impuissance masculine réalisée du 7 au 25 Octobre 1994 pour les laboratoires Pharmacia Up John ( échantillon de 1000 hommes > 18 ans représentatif de la population national).*
- 2.61. Solderdahl DW, Knight RW, Hansberry KL.  
*Erectile dysfunction following resection of the prostate.* J Urol 1996; 156: 1354-1356.
- 2.62. Spira A, Bajos N et le groupe ACSF.  
*Les comportements sexuels en France.* La documentation française, Paris, 1993.
- 2.63. Solstad K, Hertoft P.  
*Frequency of sexual problems and sexual dysfunction in middle-aged Danish men.* Arch Sex Behav 1993; 22: 51-58.

2.64. Spector IP, Carey MP.

*Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature.* Arch Sex Behav 1990; 19: 389-408.

2.65. Weryha G, Leclerc J.

*Diabète et sexualité masculine: données épidémiologiques. In: Fonction sexuelle et reproductrice du diabétique.* Progrès en Andrologie 2. Buvat J, Drosdowsky M eds, Doin, Paris, 1989; 117-126.

2.66. Wilke RJ, Glick MA, Mc Carron TJ, Ender MH, Althof SE, Linet OI.

*Quality of life after alprostadil therapy in the US and Europe.* Int J Impot Res 1996; 8: 113.

2.67. Zeiss AM, Davies HD, Wood M, Tinklenberg JR.

*The incidence and correlates of erectile problems in patients with Alzheimer's disease.* Arch Sex Behav 1990; 19: 325-311.

### **3. Tài liệu thần kinh Vu-son trị liệu ( En psycho-sexologie).**

3.1. André C.

*Les thérapies cognitives,* Ed. Morisset, 1995, Paris.

3.2. Bouvard M, Cottraux J.

*Protocoles et échelles d'évaluation en psychiatrie et en psychologies.* Masson, 1996, Paris.

3.3. Brenot P.

*Impuissance masculine perspectives historiques.* L'esprit du temps. 1994, Paris.

3.4. Colson MH.

*Injections intracaverneuses et prise en charge globale des dysfonctionnements érectiles.* Sexologies, 1996; Vol nr. 20: 11-24.

3.5. Cottraux J.

*Les thérapies comportementales et cognitives.* Masson, 1990, Paris.

3.6. Fontaine O, Cottaux J, Ladouceur R.

*Cliniques de thérapie comportementale.* P. Mardaga, 1984, Bruxelles.

3.7. Masters WH, Johnson VE.

*Les mésententes sexuelles.* Robert Laffont. 1970, Paris.

3.8. Poudat FX, Jarousse N.

*Traitement comportemental des difficultés sexuelles*. Maloine SA. 1986, Paris.

3.9. Singer Kaplan H.

*La nouvelle thérapie sexuelle*. Buchet Chastel. 1979, Paris

#### **4. Tài liệu về VIAGRA**

4.1. VIAGRA (sildénafil), Brochure Produit, Science et passion de la vie, Pfizer, 1998. Đây là tài liệu căn bản nhất của viện bào chế Pfilzer.

4.2. Terret NK, Bell As, Brow D et al.

*Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction*. Bioorg and Med Chem Letters 1996; 6 (15): 1819-1824.

4.3. Dossier d'AMM VIAGRA.

4.4. Résumé des caractéristiques du produit VIAGRA. Viện bào chế Pfilzer.

4.5. Blom TJ, Beavo JA.

*Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants*. Proc Natl Acad Sci USA 1996; 93: 14188-14192.

4.6. Jeremy JJ, Ballard SA, Naylor AM et al.

*Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro*. Br J Urol 1997; 79: 958-963.

4.7. Ogrinc FG, Linet OI.

*Evaluation of real-time RigiScan monitoring in pharmacological erection*. J Urol 1995; 154: 1356-1359.

4.8. Boolell M, Allen MJ, Ballard SA et al.

*Sildenafil: an orally active type-5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction*. Int J Impot Res 1996; 8: 47-52.

4.9. Boolell M, Gepi-Attee S, Gingell JC et al.

*Sildenafil, a novel effective oral therapy for male erectile dysfunction*. Br J Urol 1996; 78: 257-261.

- 4.10. Goldstein I; Lue TF, Padma-Nathan H et al.  
*Oral sildenafil in the treatment of erectile dysfunction.* N Engl J Med 1998, 338: 1397-1404.
- 4.11. Andersen BL, Broffitt B.  
*Is there a reliable and valid self-report measure of sexual behavior?* Arch Sex Behav 1988; 17 (6): 509-525.
- 4.12. Conte HR.  
*Development and use of self-report techniques for assessing sexual behavior?* Arch Sex Behav 1983; 12: 555-576.
- 4.13. Rosen RC, Riley A, Wagner G et al.  
*The International Index of Erectile Function (IIEF): a multidimensional scale for assesment of erectile dysfunction.* Urology 1997; 49: 822-830.
- 4.14. NIH Consensus Developement Panel on Impotence. *NIH Consensus Conference: Impotence.* JAMA 1993; 270: 83-90.
- 4.15. Dituno JF, Young W, Dononvan WH et al.  
*The international standards booklet for neurological and functional classification of spinal-cord injury.* Paraplegia 1994; 32: 70-80.
- 4.16. Morales A, Gingell C, Collins M et al.  
*Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction.* Int J Impot Res 1998; 10: 69-74.
- 4.17. Anderson KM, Milson PWF, Odell PM et al.  
*An updated coronary risk profile: a statement for health professionals.* Circulation 1991; 83: 356-362.